Personalized Medicine Versus The Public Health: FDA Debates The “Polypill”
This article was originally published in RPM Report
FDA is beginning to solicit input from the medical community on review issues for a multi-ingredient cardiovascular product designed to control hypertension, platelet aggregation and cholesterol levels. The key issue is whether convenience and broad access make up for loss of individualized dosing. That is an important debate in the era of personalized medicine.
You may also be interested in...
An interview with newly confirmed FDA Commissioner Margaret Hamburg.
Medicare Payment Advisory Commission also considering reviving least costly alternative policy in some way, but remains relatively hesitant about changes to ASP+6%.
As Biden administration and MedPAC both work on ideas to overhaul Part B, marketers of physician-administered drugs (primarily for cancer, ophthalmology and rheumatological disorders) should prepare for a fight – but only if the broader ‘negotiation’ push fails.